Ocrevus treatment was linked to increases in myelin and reductions in iron in MS patients with paramagnetic rim lesions, per ...

An immune profile consistent with the eactivation of the Epstein-Barr virus was observed in MS patients prior to a disease ...

Columnist Susan Payrovi, MD, instinctually helps others when they're vulnerable, which often produces something called "the ...

Columnist Ben Hofmeister has found a military acronym that applies well to his life with MS: GOTWA, for his five-point contingency plan.

Transcranial direct current stimulation (tDCS) didn't outperform a sham treatment in easing fatigue in adults with multiple ...

A statistical model that takes into account clinical and demographic factors could help guide decisions about treatment in ...

Since 2013, diagnoses of multiple sclerosis (MS) in Finland take less time after symptom onset and treatments follow the ...

Tiziana and Renaissance will partner to accelerate clinical development and potential commercial launch of nasal foralumab.

B-cells were collected from people with and without MS, and those from patients had heightened antibody responses, ...

Ocrevus as a first-line treatment for early relapsing MS is better at delaying disease progression than starting with a less ...

The study estimated annual mortality rates for 5,797 individuals with MS compared with 28,807 controls with a similar age, ...

Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded ...